Qualitative Analysis of COVID-19 Vaccine Reactogenicity in Banjarmasin City, South Kalimantan During the Pandemic
DOI:
https://doi.org/10.51601/ijhp.v5i4.457Abstract
The World Health Organization (WHO) officially recognized COVID-19 as a pandemic. By March 29, 2020, global cases had reached 634,835 with 33,106 fatalities. In Indonesia, there were 1,528 confirmed infections and 136 deaths. According to Indonesia's Presidential Regulation No. 99 of 2020, the government is expediting the acquisition of COVID-19 vaccines and the vaccination program to combat the pandemic. COVID-19 has spread extensively across nearly all provinces in Indonesia. The government remains committed to gradually delivering safe, high-quality, and effective vaccines. Despite these efforts, many people remain hesitant about vaccination due to concerns over side effects and vaccine safety. This study aims to qualitatively analyze the reactogenicity of COVID-19 vaccines. Using a descriptive observational qualitative design, informants were selected through purposive sampling. Reported side effects include drowsiness, injection site pain, increased appetite, fever around 38-39°C, weakness, recurrence of asthma, chest tightness, cough, and runny nose. The most common reactions observed were fever up to 39°C (18.51%) and vomiting (11.11%).
Downloads
References
] Yu SHI1, Gang WANG1, Xiao-peng CAI1, Jing-wen DENG1, Lin ZHENG2, Hai-hong ZHU1, Min ZHENG†‡1, Bo YANG†‡2 ZC. AnOverviewOfCOVID-19. 2020;21(5):343–60.
] Nur Syahadati Retno Panenggak, Nur Shanti Retno Pembayun, Erta, Hapsari Shinta Citra Puspita Dewi, Nurhasan. Efek Samping Dan Reaktogenisitas Vaksin Covid-19: Survei Penerima Vaksin. Jurnal Ilmiah Indonesia p–ISSN: 2541-0849 e-ISSN : 2548-1398 Vol. 6, Special Issue No. 2, Desember 2021 Google Scholar
] Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020;11(December):1–19.
] Germas Kemenkes RI. Question ( Faq ) Pelaksanaan Vaksinasi Covid-. Kesmas [Internet]. 2021;2(1):1–16. Available from: kesmas.kemkes.go.id
] Kemenkes RI. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/4638/2021 Tentang Petunjuk Teknis Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (Covid-19). JurnalrespirologiOrg [Internet]. 2021;2019(2):1–4. Available from: http://www.jurnalrespirologi.org/index.php/jri/article/view/101
] Presiden Republik Indonesia. Peraturan Presiden Republik Indonesia Nomor 99 Tahun 2020 tentang Pengadaan Vaksin dan Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (COVID-19). Peratur Pres [Internet]. 2020;2019(039471):1–13. Available from: https://peraturan.bpk.go.id/Home/Details/147944/perpres-no-99-tahun-2020
] Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11(December 2019):1–17.
] Rifka Alkhilyatul Ma’rifat, I Made Suraharta IIJ. No Title 済無No Title No Title No Title. 2024;2:306–12.
] Majelis_Ulama_Indonesia. Fatwa Majelis Ulama Indonesia Nomor 02 Tahun 2021 Tentang Produk Vaksin Covid-19 dari Sinovac Life Sciences Co. Ltd. China dan PT. Bio Farma (Persero). Majelis Ulama Indones. 2022;1–8.
] Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathol Persa [Internet]. 2021;7(2):e31–e31. Available from: https://doi.org/10.34172/ipp.2021.31
] Awanis AT, Amal S, Frianto D. Perbedaan Tingkat Kepercayaan Mahasiswa Farmasi Dan Nonfarmasi Terhadap Penerimaan Vaksin Covid-19. J Buana Farma. 2021;1(3):1–5.
] Azarpanah H, Farhadloo M, Vahidov R, Pilote L. Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases. BMC Public Health. 2021;21(1):1–13.
] Nossier SA. Vaccine hesitancy: the greatest threat to COVID-19 vaccination programs. J Egypt Public Health Assoc. 2021;96(1):18–20.
] Barrett ADT, Titball RW, MacAry PA, Rupp RE, von Messling V, Walker DH, et al. The rapid progress in COVID vaccine development and implementation. npj Vaccines. 2022;7(1):19–20.
] San Francisco Ramos A, Liu Sanchez C, Bovill Rose T, Smith D, Thorn N, Galiza E, et al. Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis. Expert Rev Vaccines [Internet]. 2024;23(1):266–82. Available from: https://doi.org/10.1080/14760584.2024.2315089
] Sutton N, San Francisco Ramos A, Beales E, Smith D, Ikram S, Galiza E, et al. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines [Internet]. 2022;21(9):1301–18. Available from: https://doi.org/10.1080/14760584.2022.2098719
] Gonen T, Barda N, Asraf K, Joseph G, Weiss-Ottolenghi Y, Doolman R, et al. Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines. JAMA Netw Open. 2023;6(9):E2332813.
] Matsumura T, Takano T, Takahashi Y. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. Int Immunol. 2023;35(5):213–20.
] Ning Z. E cacy and safety of COVID- inactivated vaccine : A.
] Mahallawi WH, Mumena WA. Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines. Front Immunol. 2021;12(December):1–9.
] Sultana A, Shahriar S, Tahsin MR, Mim SR, Fatema KR, Saha A, et al. A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines. 2021;9(10):1–10.
] Bhandari B, Rayamajhi G, Lamichhane P, Shenoy AK. Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review. Biomed Res Int. 2022;2022(5).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Muliyani Muliyani, Nazhipah Isnani, Rahmi Annisa, Juwita Ramadhani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
